

Updates on Therapeutic Options for DVT and PE Prevention and Management in the ICU

Deborah J. Cook: Thromboembolic Disease in the Critically Ill: What Is the Risk?

Kenneth E. Wood: Controversies: What Is the Role of Thrombolytic Therapy and IVC Filters?

Jack Ansell: New Agents in Anticoagulation

References

1. Cook DJ, Meade M, Guyatt G, et al, Canadian Critical Care Trials Group. Clinically important deep vein thrombosis in the ICU: a survey of intensivists. *Crit Care*. 2004;8:R145-R152.
2. Crowther MA, Cook DJ, Griffith LE, et al. Deep venous thrombosis: clinically silent in the intensive care unit. *J Crit Care*. 2005;20:334-340.
3. Crowther MA, Cook DJ, et al. Baseline coagulation factors and D-dimer levels do not predict deep venous thrombosis in critically ill medical-surgical patients. *Intensive Care Med*. 2005; 31(1):48-55.
4. Ibrahim EH, Irequi M, Prentice D, et al. Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. *Crit Care Med*. 2002;30:771-774.
5. Griffith L. Attributable morbidity and mortality of DVT. *Crit Care Med* 2007 35; 12:A628.
6. Geerts W, Cook D, Selby R, Etchells E. Venous thromboembolism and its prevention in critical care. *J Crit Care*. 2002;17:95-104.
7. Douketis J, Cook, et al; Canadian Critical Care Trials Group. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. *Arch Intern Med*. 2008;168(16):1805-1812.
8. Cook DJ, Douketis J, et al; Canadian Critical Care Trials Group. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency: prevalence, incidence and risk factors. *Crit Care*. 2008; 12(2):R32.
9. Goldhaber SZ. Venous thromboembolism in the intensive care unit; the last frontier for prophylaxis. *Chest*. 1998;113:5-7.

10. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126(3 Suppl):338S-400S.
11. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. *N Engl J Med*. 1998;338:409-415.
12. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risqué d'Embolie Pulmonaire par Interruption Cave) randomized study. *Circulation*. 2005;112:416-422.
13. White RH, Zhou H, Kim J, Romano PS. A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. *Arch Intern Med*. 2000;160:2033-2041.
14. Hann CL, Streiff MB. The role of vena caval filters in the management of venous thromboembolism. *Blood Rev*. 2005;19:179-202.
15. Crochet DP, Brunel P, Trogrlic S, et al. Long-term follow-up of Vena Tech-LGM filter: predictors and frequency of caval occlusion. *J Vasc Interv Radiol*. 1999;10:137-142.
16. Baglin TP, Brush J, Streiff M; British Committee for Standards in Haematology Writing Group. Guidelines on use of vena cava filters. *Br J Haematol*. 2006;134:590-595.
17. Turpie AG, Bauer KA, Ericksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. *Arch Intern Med*. 2002;162:1833-1840.
18. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. *Lancet*. 2007;370:949-956.
19. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. *J Thromb Haemost*. 2007;5:2178-2185.
20. Ginsberg JS, Davidson BL, Comp PC, et al; The RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. *J Arthroplasty*. 2009;24:1-9.

21. Lassen MR, Gallus AS, Pineo GF, et al. Randomized double-blind comparison of apixaban with enoxaparin for thromboprophylaxis after knee replacement: the ADVANCE-1 trial. Abstract presented at: The American Society of Hematology 50th Annual Meeting and Exposition; December 6-9, 2008; San Francisco, CA. <http://ash.confex.com/ash/2008/webprogram/Paper4437.html> Accessed April 1, 2009.
22. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *N Engl J Med.* 2008;358:2765-2775.
23. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. *Lancet.* 2008;372:31-39.
24. Lassen MR, Ageno W, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *N Engl J Med.* 2008;358(26):2776-2786.
25. Turpie AG, Lassen MR, Kakkar AK, et al. A meta-analysis of three pivotal studies of rivaroxaban—a novel, oral, direct factor XA inhibitor—for thromboprophylaxis after orthopedic surgery. Abstract presented at: The 20th International Congress on Thrombosis; June 25-28, 2008; Athens, Greece.